Organon & Co. financial data

Symbol
OGN on NYSE
Industry
Pharmaceutical Preparations
Location
30 Hudson Street, Fl 33, Jersey City, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 161 % +1.12%
Quick Ratio 47.2 % +7.45%
Debt-to-equity -10.2K %
Return On Equity -857 % -823%
Return On Assets 8.49 % +21.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 257M shares +0.75%
Common Stock, Shares, Outstanding 257M shares +0.75%
Entity Public Float 5.3B USD -38.4%
Common Stock, Value, Issued 3M USD 0%
Weighted Average Number of Shares Outstanding, Basic 257M shares +0.76%
Weighted Average Number of Shares Outstanding, Diluted 259M shares +1.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.35B USD +2.89%
Research and Development Expense 472M USD +103%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 655M USD -25.7%
Income Tax Expense (Benefit) -345M USD -370%
Net Income (Loss) Attributable to Parent 1B USD +32.6%
Earnings Per Share, Basic 3.9 USD/shares +31.3%
Earnings Per Share, Diluted 3.88 USD/shares +31.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 704M USD +116%
Accounts Receivable, after Allowance for Credit Loss, Current 1.62B USD -3.29%
Inventory, Net 1.29B USD +7.34%
Other Assets, Current 901M USD +18.4%
Assets, Current 4.51B USD +13.9%
Property, Plant and Equipment, Net 1.16B USD +4.69%
Operating Lease, Right-of-Use Asset 173M USD -19.5%
Goodwill 4.6B USD 0%
Assets 12.2B USD +10.7%
Accounts Payable, Current 1.24B USD +11.5%
Liabilities, Current 2.76B USD +15.4%
Deferred Income Tax Liabilities, Net 60M USD +87.5%
Operating Lease, Liability, Noncurrent 125M USD -16.7%
Other Liabilities, Noncurrent 548M USD +39.4%
Liabilities 12B USD +4.13%
Accumulated Other Comprehensive Income (Loss), Net of Tax -612M USD -14.8%
Retained Earnings (Accumulated Deficit) 690M USD
Stockholders' Equity Attributable to Parent 144M USD
Liabilities and Equity 12.2B USD +10.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 76M USD -33.3%
Net Cash Provided by (Used in) Financing Activities -74M USD +77.3%
Net Cash Provided by (Used in) Investing Activities -96M USD -77.8%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 257M shares +0.75%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -118M USD +52.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 704M USD +116%
Deferred Tax Assets, Valuation Allowance 309M USD +494%
Deferred Tax Assets, Gross 1.17B USD +174%
Operating Lease, Liability 171M USD -14.1%
Depreciation 32M USD +14.3%
Payments to Acquire Property, Plant, and Equipment 46M USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 921M USD +13.7%
Lessee, Operating Lease, Liability, to be Paid 189M USD -14.1%
Operating Lease, Liability, Current 46M USD -6.12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 48M USD -2.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 52M USD -7.14%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +25%
Deferred Income Tax Expense (Benefit) 5M USD +66.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18M USD -14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 29M USD -37%
Deferred Tax Assets, Operating Loss Carryforwards 35M USD -46.2%
Unrecognized Tax Benefits 115M USD +23.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14M USD -22.2%
Deferred Tax Assets, Net of Valuation Allowance 863M USD +130%
Share-based Payment Arrangement, Expense 108M USD +22.7%
Interest Expense 525M USD +6.93%